Avalyn Pharma (AVLN) vs Generate Biomedicines (GENB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Avalyn Pharma is the larger company by market cap ($1.26 billion vs $1.23 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVLN | GENB |
|---|---|---|
| Share price | $28.40 | $9.54 |
| Market cap | $1.26B | $1.23B |
| 1-day change | -1.05% | -8.00% |
| EPS (TTM) | $-3.96 | $-2.49 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $40.17 | $22.67 |
| 52-week low | $22.24 | $9.40 |
| Distance from 52-week high | -29.30% | -57.92% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +114.79% | +183.02% |
| Average volume | 352.95K | 1.24M |
| Shares outstanding | 44.52M | 129.10M |
| Employees | 56 | 312 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Avalyn Pharma
AVLN stock →Avalyn Pharma Inc. operates as a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
About Generate Biomedicines
GENB stock →Generate Biomedicines, Inc., engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics in the United States. It uses protein-based modalities for drug development.
Health Care · Biotechnology: Pharmaceutical Preparations · 312 employees
AVLN vs GENB FAQ
Which is bigger, Avalyn Pharma or Generate Biomedicines?
Avalyn Pharma (AVLN) is larger, with a market capitalization of $1.26B compared with $1.23B for Generate Biomedicines (GENB).
Are Avalyn Pharma and Generate Biomedicines in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.